Inflation Reduction Act: Resources and Advocacy

The Inflation Reduction Act, signed in August 2022, includes provisions that impact community pharmacy.

For inquiries/issues related to the IRA or the Medicare Drug Price Negotiation Program, members can contact [email protected]. 

Please see below for additional resources on the Inflation Reduction Act.

Webinars

NCPA Members meet Beacon MFP

NCPA Members meet Beacon MFP

Maximum Fair Price and your Cash Flow

Maximum Fair Price and your Cash Flow

Hear from NCPA Senior Director of Professional Affairs, Lisa Schwartz, PharmD, RPh about how the maximum fair price will affect your cash flow. Walk through reimbursement examples and reconciliation before implementation in 2026.

Medicare Transaction Facilitator Enrollment for Dispensing Entities Webinar

Medicare Transaction Facilitator Enrollment for Dispensing Entities Webinar

340B-rrr: Feeling the Chill of the IRA

As the Inflation Reduction Act continues to reshape drug pricing and reimbursement, the 340B program finds itself in the middle of a policy snowstorm. This timely session explores how the IRA's provisions—especially around Medicare price negotiations and manufacturer rebates—are impacting covered entities and contract pharmacies. Join us for a brisk walk through the latest developments, featuring insights from leading industry experts and a representative from a covered entity who will share real-world perspectives from the front lines. Whether you're navigating compliance, managing operations, or advocating for program sustainability, this session will help you stay ahead of the freeze.

Update as of January 2, 2026: Pharmacies should know that the 340B Rebate Model Pilot Program (the Pilot), previously set to be in effect January 1, 2026 and that NCPA previously reported on and covered in this webinar, is currently paused. The information in this webinar pertaining to the Pilot is still relevant, but will not go into effect until a later time. NCPA will keep its members posted on developments.

 

NCPA Resources

  • NCPA member summary on CMS’ CY 2026 Medicare Part D/MA final rule (April 2025)
  • NCPA Medicare Drug Price Negotiation Program talking points (November 2024)
  • NCPA member summary on CMS’ guidance on the Medicare Drug Price Negotiation Program (October 2024)
  • NCPA member summary on CMS’ guidance on the Medicare Prescription Payment Plan (MPPP)/”co-pay smoothing” (July 2024)

Centers for Medicare and Medicaid Services (CMS) Resources

Studies

  • Avalere study showing the Medicare Drug Price Negotiation program’s significant impact on beneficiaries, independent pharmacies (March 2025)
  • 3 Axis Advisors study showing financial impact of the Medicare Drug Price Negotiation program on independent pharmacies (January 2025)

NCPA Comments